基因测序 z-bo 2020-09-15 397

　　The Chinese government recently launched a medical research project called the "One Hundred Thousand Genome Project", which plans to sequence the genome to effectively identify the genes that cause cancer and other difficult diseases. Local media commented that if this plan is successfully implemented and succeeded, it will be a major breakthrough in the field of medicine. In the future, the treatment of cancer will no longer be carried out through chemotherapy.

　　It is understood that the "One Hundred Thousand Genome Project" requires an investment of 300 million pounds to integrate a large amount of data obtained from scientific research into the British public medical system. The UK will participate in the sequencing of 70,000 genomes out of a total of 100,000 genomes. It can be said that the "One Hundred Thousand Genome Project" is an "upgraded version" of the "Thousand Genome Project" previously launched by the UK. The new "One Hundred Thousand Genome Project" is not only to sequence specific "cancer genes" of cancer patients, but to "whole genome sequencing". Since May this year, the UK has started research in hospitals in London and Cambridge, and universities and research institutions across the UK are also assisting the British Ministry of Health in advancing this plan. According to the report, the UK has currently completed 100 genome sequencing, which will reach more than 1,000 within the year, 10,000 in 2015, and all will be completed in 2017.

　　Burns, a doctor from the Crawford Clinic in London, UK, told our reporter that chemotherapy is still the main way to treat cancer so far, but it has more side effects. Therefore, it is necessary to find alternative treatments that are less harmful to the human body. Drawing a genome map will help to find alternative treatments for cancer in the future, and a correct understanding of the genome map will also help diagnose, prevent and treat cancer and other difficult diseases.

　　The British "Daily Mail" reported that cancer gene sequencing has been rewarded, and a number of drugs have been developed specifically for a specific cancer, such as Herceptin for the treatment of breast cancer. The promotion and implementation of the new "One Hundred Thousand Genome Project" is expected to enable further breakthroughs in cancer research. If the plan can be implemented in a comprehensive and in-depth manner and achieve major success, chemotherapy will become history. Some experts predict that in 20 years, chemotherapy will withdraw from the stage of history.

　　In order to strengthen international cooperation, raise funds and launch technical cooperation, the British government has invited the American biotechnology company Ilumina as the "priority cooperation unit" of the plan. The company's gene sequencing method has always been a market leader and has extensive influence. The "One Hundred Thousand Genome Project" also promised to take strict confidentiality measures for genetic data. Although the final research results will be made public, the personal information of each patient participating in the project will never be disclosed.